Green tea attenuates cardiovascular remodeling and metabolic symptoms in high carbohydrate-fed rats

Current Pharmaceutical Biotechnology

Volumn 11, Issue 8, 2010, Pages 881-886

  Rickman, Celestine ^a   Iyer, Abishek ^a   Chan, Vincent ^b   Brown, Lindsay ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

Author keywords

Diabetes; Green tea; Obesity; Oxidative stress; Rats; Remodeling

Indexed keywords

COLLAGEN; FRUCTOSE; GREEN TEA EXTRACT; MALONALDEHYDE; STARCH; ANTIOXIDANT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE DIET; CONTROLLED STUDY; ECHOCARDIOGRAPHY; EX VIVO STUDY; GLUCOSE INTOLERANCE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE COMPLIANCE; HISTOLOGY; HYPERTENSION; IN VIVO STUDY; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; SYSTOLIC BLOOD PRESSURE; ANIMAL; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HEART VENTRICLE REMODELING; METABOLIC DISORDER; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; TEA;

RATTUS; RATTUS NORVEGICUS; ZEA MAYS;

ANIMALS; ANTIOXIDANTS; BLOOD GLUCOSE; BODY WEIGHT; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; DIETARY CARBOHYDRATES; ECHOCARDIOGRAPHY; FRUCTOSE; GLUCOSE INTOLERANCE; HYPERTENSION; MALE; METABOLIC DISEASES; OXIDATIVE STRESS; RATS; STARCH; TEA; VENTRICULAR REMODELING;

EID: 79957962795     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920110793261980     Document Type: Article

References (34)

1. Fang, Z.Y.; Prins, J.B.; Marwick, T.H. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr. Rev. 2004, 25. 543-567.
2. Mytas, D.Z.; Stougiannos, P.N.; Zairis, M.N.; Foussas, S.G.; Pyrgakis, V.N.; Kyriazis, I.A. Diabetic myocardial disease: pathophysiology, early diagnosis and therapeutic options. J. Diabetes Complications. 2009, 23. 273-282.
3. Van Horn, L.; McCoin, M.; Kris-Etherton, P.M.; Burke, F.; Carson, J.A.; Champagne, C.M.; Karmally, W.; Sikand, G. The evidence for dietary prevention and treatment of cardiovascular disease. J. Am. Diet. Assoc. 2008, 108. 287-331.
4. Tappy, L.; Le, K.A. Metabolic effects of fructose and the worldwide increase in obesity. Physiol. Rev. 2010, 90. 23-46.
5. Chen, D.; Wang, M.W. Development and application of rodent models for type 2 diabetes. Diabetes Obes. Metab. 2005, 7. 307-317.
6. Islam, M.S.; Loots du, T. Experimental rodent models of type 2 diabetes: a review. Methods Find. Exp. Clin. Pharmacol. 2009, 31. 249-261.
7. Suzuki, E.; Yorifuji, T.; Takao, S.; Komatsu, H.; Sugiyama, M.; Ohta, T.; Ishikawa-Takata, K.; Doi, H. Green tea consumption and mortality among Japanese elderly people: the prospective Shizuoka elderly cohort. Ann. Epidemiol. 2009, 19. 732-739.
8. Khan, N.; Mukhtar, H. Tea polyphenols for health promotion. Life Sci. 2007, 81. 519-533.
9. Thielecke, F.; Boschmann, M. The potential role of green tea catechins in the prevention of the metabolic syndrome-a review. Phytochemistry. 2009, 70. 11-24.
10. Cabrera, C.; Artacho, R.; Gimenez, R. Beneficial effects of green tea-a review. J. Am. Coll. Nutr. 2006, 25. 79-99.
11. Clement, Y. Can green tea do that? A literature review of the clinical evidence. Prev. Med. 2009, 49. 83-87.
12. Bose, M.; Lambert, J.D.; Ju, J.; Reuhl, K.R.; Shapses, S.A.; Yang, C.S. The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. J. Nutr. 2008, 138. 1677-1683.
13. Wu, L.Y.; Juan, C.C.; Hwang, L.S.; Hsu, Y.P.; Ho, P.H.; Ho, L.T. Green tea supplementation ameliorates insulin resistance and increases glucose transporter IV content in a fructose-fed rat model. Eur. J. Nutr. 2004, 43. 116-124.
14. Stangl, V.; Lorenz, M.; Stangl, K. The role of tea and tea flavonoids in cardiovascular health. Mol. Nutr. Food Res. 2006, 50. 218-228.
15. Fenning, A.; Harrison, G.; Rose'meyer, R.; Hoey, A.; Brown, L. l-Arginine attenuates cardiovascular impairment in DOCA-salt hypertensive rats. Am. J. Physiol. Heart. Circ. Physiol. 2005, 289. 1408-1416.
16. Litwin, S.E.; Katz, S.E.; Morgan, J.P.; Douglas, P.S. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation. 1994, 89. 345-354.
17. Brown, L.; Duce, B.; Miric, G.; Sernia, C. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. J. Am. Soc. Nephrol. 1999, 10. S143-S148.
18. Chan, V.; Hoey, A.; Brown, L. Improved cardiovascular function with aminoguanidine in DOCA-salt hypertensive rats. Br. J. Pharmacol. 2006, 148. 902-908.
19. Iyer, A.; Fenning, A.; Lim, J.; Le, G.T.; Reid, R.C.; Halili, M.A.; Fairlie, D.P.; Brown, L. Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Br. J. Pharmacol. 2010, 159. 1408-1417.
20. Balentine, D.A.; Wiseman, S.A.; Bouwens, L.C. The chemistry of tea flavonoids. Crit. Rev. Food Sci. Nutr. 1997, 37. 693-704.
21. Wolfram, S.; Raederstorff, D.; Preller, M.; Wang, Y.; Teixeira, S.R.; Riegger, C.; Weber, P. Epigallocatechin gallate supplementation alleviates diabetes in rodents. J. Nutr. 2006, 136. 2512-2518.
22. Takimoto, E.; Kass, D.A. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension. 2007, 49. 241-248.
23. Hamilton, C.A.; Miller, W.H.; Al-Benna, S.; Brosnan, M.J.; Drummond, R.D.; McBride, M.W.; Dominiczak, A.F. Strategies to reduce oxidative stress in cardiovascular disease. Clin. Sci., (Lond). 2004, 106. 219-234.
24. Willcox, B.J.; Curb, J.D.; Rodriguez, B.L. Antioxidants in cardiovascular health and disease: key lessons from epidemiologic studies. Am. J. Cardiol. 2008, 101. 75D-86D.
25. Li, H.L.; Huang, Y.; Zhang, C.N.; Liu, G.; Wei, Y.S.; Wang, A.B.; Liu, Y.Q.; Hui, R.T.; Wei, C.; Williams, G.M.; Liu, D.P.; Liang, C.C. Epigallocathechin-3 gallate inhibits cardiac hypertrophy through blocking reactive oxidative species-dependent and-independent signal pathways. Free Radic. Biol. Med. 2006, 40. 1756-1775.
26. Papparella, I.; Ceolotto, G.; Montemurro, D.; Antonello, M.; Garbisa, S.; Rossi, G.; Semplicini, A. Green tea attenuates angiotensin II-induced cardiac hypertrophy in rats by modulating reactive oxygen species production and the Src/epidermal growth factor receptor/Akt signaling pathway. J. Nutr. 2008, 138. 1596-1601.
27. Hinglais, N.; Huedes, D.; Nicoletti, A.; Manset, C.; Laurent, M.; Bariety, J.; Michel, J. Colocalization of myocardial fibrosis and inflammatory cells in rats. Lab. Invest. 1994, 70. 286-294.
28. Nicoletti, A.; Michel, J.B. Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc. Res. 1999, 41. 532-543.
29. Rutschow, S.; Li, J.; Schultheiss, H.P.; Pauschinger, M. Myocardial proteases and matrix remodeling in inflammatory heart disease. Cardiovasc. Res. 2006, 69. 646-656.
30. Levick, S.; Loch, D.; Rolfe, B.; Reid, R.C.; Fairlie, D.P.; Taylor, S.M.; Brown, L. Antifibrotic activity of an inhibitor of group IIA secretory phospholipase A2 in young spontaneously hypertensive rats. J. Immunol. 2006, 176. 7000-7007.
31. Koyama, Y.; Abe, K.; Sano, Y.; Ishizaki, Y.; Njelekela, M.; Shoji, Y.; Hara, Y.; Isemura, M. Effects of green tea on gene expression of hepatic gluconeogenic enzymes in vivo. Planta. Med. 2004, 70. 1100-1102.
32. Basu, A.; Lucas, E.A. Mechanisms and effects of green tea on cardiovascular health. Nutr. Rev. 2007, 65. 361-375.
33. Brown, A.L.; Lane, J.; Coverly, J.; Stocks, J.; Jackson, S.; Stephen, A.; Bluck, L.; Coward, A.,; Hendrickx, H. Effects of dietary supplementation with the green tea polyphenol epigallocatechin-3-gallate on insulin resistance and associated metabolic risk factors: randomized controlled trial. Br. J. Nutr. 2009, 101. 886-894.
34. Babu, P.V.; Liu, D. Green tea catechins and cardiovascular health: an update. Curr. Med. Chem. 2008, 15. 1840-1850.